Chemoresistance is currently the main cause of failure in the treatment of cancer which, despite extensive research, remains unsolved. In this report the theoretical assumptions underlying antiangiogenic therapy are described and future perspectives and limits are discussed.
AuerbachW., AuerbachR.Angiogenesis in cancer: A review.Pharmacol Ther1994; 63: 265–311.
11.
GaspariniG., HarrisA.L.Does improved control of tumor growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?Eur J Cancer1994; 30A: 201–6.
12.
GaspariniG.Angiogenesis research up to 1996, a commentary on the state of the art and suggestions for future studies.Eur J Cancer1996: 32A: 2379–85.
13.
GaspariniG., PrestaM.Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation.Ann Oncol1996: 7: 441–4.
14.
FolkmanJ.New perspectives in clinical oncology from angiogenesis research.Eur J Cancer1996: 32A: 2534–9.
15.
AlbiniA.Tumor and endothelial cell invasion of basement membranes.Pathol Oncol Res1998; 4(3): 230–41.
16.
BoehmT., FolkmanJ., BrowderT., O'ReillyM.S.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.Nature1997: 390: 404–7.
